Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Pasteur, AstraZeneca Link To Develop MEDI8897 Infant RSV Vaccine

Executive Summary

Sanofi Pasteur and AstraZeneca will collaborate over the UK pharma's monoclonal antibody MEDI8897 to develop and commercialize a pediatric vaccine against respiratory syncytial virus.

Advertisement

Related Content

Keeping Track: CDER Approves Its First Two Novel Agents Of 2019
Sobi Taps AstraZeneca's RSV Therapies, Both Current And Future, For US Expansion
RSV Market: An Unmet Clinical Need For ReViral, And Big Pharma Too
Ablynx, Bioverativ Buys Drive Sanofi's Hematology Reign
New EU Guidance To Boost Development Of Vaccines And Treatments For RSV Infections
FDA Panel To Weigh Animal, Adult Human Data For Initiation Of RSV Vaccine Trials In Infants
Deal Watch: Otsuka’s Neurovance Buy Adds ADHD Candidate To CNS Pipeline
AstraZeneca’s Seasoned Dealmaker Grady On Strategy To Grow Pipeline
Is AstraZeneca/Sanofi Library Exchange Open Innovation's Future?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098339

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel